Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
84597 trials found · Page 27 of 4230
-
Major trial tests new drug combo against advanced lung cancer
Disease control Recruiting nowThis study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is eith…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
Off-the-Shelf cancer fighter: new 'Double-Target' cell therapy enters human trials
Disease control Recruiting nowThis study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It ta…
Phase: PHASE1, PHASE2 • Sponsor: AvenCell Therapeutics, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
One-Shot gene therapy trial offers hope for infants with devastating muscle disease
Disease control Recruiting nowGB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months …
Phase: PHASE1, PHASE2 • Sponsor: Gemma Biotherapeutics • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Blood test guides chemo to stop Cancer's return
Disease control Not yet recruitingThis study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with curatively resected esophageal squamous cell carcinoma.
Phase: PHASE3 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Apr 22, 2026 14:58 UTC
-
Race against time: new stroke treatment strategy aims to save brain function
Disease control Recruiting nowThis study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before …
Phase: PHASE3 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New pill aims to slow devastating brain disease
Disease control Recruiting nowThe goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genet…
Phase: PHASE2, PHASE3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Personalized immune cells target advanced sarcoma in major trial
Disease control Recruiting nowThe purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Phase: PHASE3 • Sponsor: Takara Bio Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for kids with tough leukemia: early trial tests personalized cell therapy
Disease control Not yet recruitingA study to evaluate the safety and preliminary efficacy of CLL-1-targeted CAR-T cell therapy in children aged 3 to 18 years with relapsed or refractory acute myeloid leukemia (r/r AML).
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New drug trial offers hope for controlling severe genetic brain disorder
Disease control Recruiting nowThe Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-…
Phase: PHASE3 • Sponsor: GRIN Therapeutics, Inc. • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
Magic mushroom therapy tested as depression treatment
Disease control Recruiting nowThe primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocyb…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Scientists test 'Living Drug' in fight against deadly brain tumor
Disease control Recruiting nowThis is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum tolerated dose (MTD)and recommended Phase 2 dose (RP2…
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
Experimental surgery offers hope to Amputation-Bound patients
Disease control Recruiting nowChronic limb-threatening ischemia (CLTI) is a serious condition that happens when blood flow to the legs or feet is severely reduced. This can lead to constant pain, wounds that don't heal, infections, and in some cases, the need for amputation. Some people with CLTI have such s…
Phase: NA • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Radiation and immunotherapy team up to fight stubborn breast cancer
Disease control Recruiting nowThe goal of this clinical trial is to test whether a "rescue" strategy can turn chemotherapy-resistant triple-negative breast cancer (TNBC) into a curable state. Patients whose tumors fail to shrink after 2 cycles of standard neoadjuvant chemotherapy will receive a short, high-pr…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Dual-Attack drug tested to shrink tumors before lung cancer surgery
Disease control Recruiting nowThis is a single-center, open-label, single-arm phase II exploratory study evaluating a perioperative regimen of iparomlimab and tuvonralimab (QL1706; a bispecific PD-1/CTLA-4 antibody) combined with platinum-based chemotherapy in patients with resectable or potentially resectabl…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
New hope for advanced lung cancer patients with rare genetic marker
Disease control Recruiting nowThe purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cance…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC
-
Major trial tests promising new drug combo against tough blood cancer
Disease control Recruiting nowThis study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
New drug aimed at making risky sickle cell cure more reliable
Disease control Not yet recruitingThis trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study …
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Major trial tests promising new drug cocktail for Tough-to-Treat stomach cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Aden…
Phase: PHASE3 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Apr 22, 2026 14:59 UTC
-
Major trial challenges 'No-Go Zone' for brain surgery
Disease control Not yet recruitingThis clinical study is a high-level evidence-based medical research project designed to compare the efficacy differences between stereotactic aspiration and conservative treatment in patients with brainstem hemorrhage. Brainstem hemorrhage is a life-threatening condition with ext…
Phase: NA • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
New hope for oral cancer: immunotherapy combo aims to stop recurrence
Disease control Recruiting nowThis is a multicenter, open-label, randomized phase III clinical trial evaluating perioperative treatment with sintilimab combined with chemotherapy in patients with locally advanced oral squamous cell carcinoma. Despite standard treatment with surgery followed by postoperative …
Phase: PHASE3 • Sponsor: Qunxing Li,MD • Aim: Disease control
Last updated Apr 22, 2026 14:58 UTC